Based on clinical trial data, the benefit-to-risk equation, contraindications, and experience with ECP at your institution, which patients with scleroderma are you treating with ECP, and what strategies are you deploying to optimize outcomes?
Based on clinical trial data, the benefit-to-risk equation, contraindications, and experience with ECP at your institution, which patients with scleroderma are you treating with ECP, and what strategies are you deploying to optimize outcomes?
Created by
Presenter
Ian Odell, MD, PhD
Assistant Professor
Dermatology Director, Adult Primary Care Center
Scleroderma and Myositis Program
Yale University School of Medicine